Tamiflu not a panacea to shortage

The recent FDA approval of Tamiflu oseltamivir to prevent influenza infection comes in a flu season where there is a shortage of available vaccine. But the neuraminidase inhibitor developed by Gilead Sciences Inc. and partner F. Hoffmann-La

Read the full 377 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE